Home DermaSensor device launched commercially as the world’s first point-and-click skin cancer detection tool for primary care providers

DermaSensor device launched commercially as the world’s first point-and-click skin cancer detection tool for primary care providers

Press Release: November 30, 2020

DermaSensor Inc., a health technology company designing tools to better equip primary care providers for skin cancer checks, today announced the launch of their new point-and-click device in Australia and New Zealand. The company also recently received CE Mark for use of its product in Europe. The DermaSensor device was designed as an objective tool to support clinicians’ assessment of suspicious lesions for the most common forms of skin cancer.

After frontline providers identify any lesions of concern for skin cancer on their patients, they gently touch the small, non-invasive device tip to the lesion. The tool takes instant spectroscopic recordings, emitting light and capturing the wavelengths of light that scatter off cellular structures beneath the skin’s surface and then back to the spectral sensor. A proprietary algorithm analyzes the light and provides an immediate “Higher Risk” or “Lower Risk” result, all in less than 30 seconds.

“Globally there are around 8 million new skin cancer cases each year, and about two-thirds of skin issues are first evaluated by non-specialists,” states DermaSensor’s CEO, Cody Simmons. “If the world’s millions of primary care providers were equipped with an easy-to-use, low-cost tool that helped them better assess skin cancer, we believe that tens of thousands of lives could be saved each year since nearly all skin cancer is curable if detected early. That is why our company has spent the last decade conducting several clinical studies and engineering our current miniaturized one-pound, hand- held device from what used to be a 30-pound, microwave-size spectroscopy system.”

In addition to their commercial launch, DermaSensor is also announcing today the results of a U.S. study that show the clinical utility potential of the DermaSensor device. In a randomized, prospective study with 57 primary care physicians, these physicians made over 5,000 assessments of skin lesions. The study results showed that physicians’ correctly referred or biopsied cancerous lesions 13 percent more when the DermaSensor output was available to them, compared to their evaluations with no device output. The physicians' cancer sensitivity increased from 81% to 94%, and this improvement was statistically significant (p <.0001).

“Approximately two-thirds of Australians are diagnosed with skin cancer, so it’s been recognized as a major public health issue in Australia for decades,” says DermaSensor’s Kevin Scrimshaw, Commercial Director for Australia and New Zealand. “Despite that, there are still thousands of deaths from skin cancer every year here, and a great portion of those could have been prevented if those skin cancers were caught early. DermaSensor is launching to support Australia’s GPs in the fight against skin cancer by assisting them in identifying skin cancers. The earlier, the better.”

The DermaSensor device is currently CE Marked and is registered and available for sale in Australia and New Zealand. In the United States, the device is currently investigational and not yet available for sale. To learn more about the device and how to purchase, please visit Dermasensor.com.

About DermaSensor Inc.:

DermaSensor Inc. is a health technology company designing non-invasive tools to better equip primary care providers for skin cancer checks. The DermaSensor device is an affordable, handheld tool that uses machine learning and spectroscopy to evaluate skin lesions for potential cancer in a matter of seconds. DermaSensor’s mission is to improve outcomes and save on healthcare costs by providing broad access to effective skin cancer checks since the large majority of Americans do not receive an annual skin check.

Forward-Looking Statements:

This press release includes forward-looking statements. The expectations, estimates, and projections of DermaSensor Inc. may differ from its actual results and you should not rely on these forward-looking statements as predictions of future events. DermaSensor does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Notes to editors

For more information, please contact:

Jasmine Rochelle

Tel: +1 919-525-9906

Email: jasmine@alphaechoagency.com

Visit the newsroom of: Jasmine Rochelle